Evidence map›Paper›PMID 37784023›Full record

ArticleBMC infectious diseases2023

Epidemiology and clinical characteristics of patients with carbapenem-resistant enterobacterales infections: experience from a large tertiary care center in a developing country.

Banan M Aiesh, Yazan Maali, Farah Qandeel, Siwar Omarya, Shatha Abu Taha, Suha Sholi, Ali Sabateen, Adham Abu Taha, Sa'ed H Zyoud

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Improved diagnostic stewardship in carbapenem-resistantJournal of medical microbiology · 2025
    Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Banan M AieshDepartment of Infection Prevention and Control, An-Najah National University Hospital, Nablus, 44839, Palestine. b.ayesh@najah.edu.
Yazan MaaliDepartment of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Farah QandeelDepartment of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Siwar OmaryaDepartment of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Shatha Abu TahaDepartment of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Suha SholiDepartment of General Surgery, An-Najah National University Hospital, Nablus, 44839, Palestine.
Ali SabateenDepartment of Infection Prevention and Control, An-Najah National University Hospital, Nablus, 44839, Palestine.
Adham Abu TahaDepartment of Biomedical Sciences, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine. aabutaha@najah.edu.
Sa'ed H ZyoudDepartment of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
An-Najah National University · PSNational University Hospital · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarbapenem-resistant Enterobacterales (CREs) are a significant source of healthcare-associated infections. These bacteria are difficult to treat and have a high mortality rate due to high rates of antibiotic resistance. These pathogens are also linked to major outbreaks in healthcare institutions especially those with limited resources in infection prevention and control (IPC). Therefore, our study aimed to describe the epidemiology and clinical characteristics of patients with carbapenem-resistant Enterobacteriaceae in a referral hospital in a developing country.

methodsThis was a retrospective cross-sectional study that included 218 patients admitted to An-Najah National University Hospital between January 1, 2021, and May 31, 2022. The target population was all patients with CRE infection or colonization in the hospital setting.

resultsOf the 218 patients, 135 had CR-Klebsiella pneumoniae (61.9%), and 83 had CR-Escherichia coli (38.1%). Of these, 135 were male (61.9%) and 83 were female (38.1%), with a median age of 51 years (interquartile range 24-64). Malignancy was a common comorbidity in 36.7% of the patients. Approximately 18.3% of CRE patients were obtained from patients upon admission to the emergency department, the largest percentage among departments. Most CRE pathogens were isolated from rectal swabs, accounting for 61.3%. Among the 218 patients, colistin was the most widely used antimicrobial agent (13.3%). CR- E. coli showed resistance to amikacin in 23.8% of the pathogens tested and 85.7% for trimethoprim/sulfamethoxazole compared to CR- K. pneumonia, for which the resistance to trimethoprim/sulfamethoxazole was 74.1%, while for amikacin it was 64.2%. Regarding meropenem minimum inhibitory concentration, 85.7% of CR- E. coli were greater than 16 µg/mL compared to 84% of CR- K. pneumonia isolates.

conclusionThis study found that CRE is frequently reported in this tertiary care setting, implying the presence of selective pressure and transmission associated with healthcare setting. The antibiotics tested showed a variety of resistance rates, with CR-K. pneumoniae being more prevalent than CR-E. coli, and exhibiting an extremely high resistance pattern to the available therapeutic options.

Indexed as

CarbapenemsPneumoniaAmikacinAnti-Bacterial Agentsbeta-LactamasesCross-Sectional StudiesDeveloping CountriesEscherichia coliFemaleHumansKlebsiella pneumoniaeMaleMicrobial Sensitivity TestsMiddle AgedRetrospective StudiesSulfamethoxazoleAmikacinAnti-Bacterial Agentsbeta-LactamasesCarbapenemsSulfamethoxazoleTrimethoprimCarbapenem resistant EnterobacteralesEscherichia coliKlebsiella pneumoniaeMeropenemResistance

Identifiers

PMID37784023
PMCPMC10544366
OpenAlexW4387264663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.